Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBP608 vs Varivax in Healthy Children
NCT03114943Phase 3Completed
- Sponsor
- SK bioscience
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Skyvaricella in varicella (VZV) (2 arms), sponsored by SK bioscience. Primary endpoint: Seroconversion Rate by Fluorescent Antibody to Membrane Antigen Assay at 6 weeks. Started Jul 2016; status: completed.
02
Drugs
Skyvaricella
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT03114943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114943.